Argenx (ARGX)
(Delayed Data from NSDQ)
$542.00 USD
-6.49 (-1.18%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $540.75 -1.25 (-0.23%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
ARGX 542.00 -6.49(-1.18%)
Will ARGX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARGX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARGX
Argenx (ARGX) Moves 4.0% Higher: Will This Strength Last?
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
ARGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Best Momentum Stocks to Buy for July 31st
New Strong Buy Stocks for July 31st
Other News for ARGX
Argenx price target raised by EUR 40 at UBS
Argenx price target raised by $40 at UBS, here's why
J&J submits FDA application for myasthenia gravis drug nipocalimab
argenx to Present at Upcoming Investor Conferences
PGIM Jennison Health Sciences Fund Q2 2024 Commentary